[go: up one dir, main page]

CA2067341A1 - Methode de synthese des derives de la prostaglandine - Google Patents

Methode de synthese des derives de la prostaglandine

Info

Publication number
CA2067341A1
CA2067341A1 CA2067341A CA2067341A CA2067341A1 CA 2067341 A1 CA2067341 A1 CA 2067341A1 CA 2067341 A CA2067341 A CA 2067341A CA 2067341 A CA2067341 A CA 2067341A CA 2067341 A1 CA2067341 A1 CA 2067341A1
Authority
CA
Canada
Prior art keywords
alkyl
synthesis
hydroxyl
halogen
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2067341A
Other languages
English (en)
Other versions
CA2067341C (fr
Inventor
Bahram Resul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2067341A1 publication Critical patent/CA2067341A1/fr
Application granted granted Critical
Publication of CA2067341C publication Critical patent/CA2067341C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Méthode de préparation d'analogues 13,14-dihydro-17-phénylés de la PGF2a ou de la PGE2 comprenant une étape d'hydrogénation de la double liaison d'un composé intermédiaire (I) sans désoxygénation de l'alcool allylique de façon à obtenir les composés intermédiaires (II et III) où R représente un hydrogène ou au moins un halogène, un hydroxyle, un cyanure, un alkyle (de préférence à 1-4 atomes de carbone), un hydroxyalkyle, un trifluorométhyle ou les substituants aromatiques ou hétéroaromatiques, R1 et R2, sur le noyau aromatique sont tous deux un hydrogène, un alkyle (de préférence à 1-4 atomes de carbone), un hydroxyle, un halogène ou un hydroxyalkyle, R3 est un O-alkyle ou un N-alkyle et P est un groupe de protection.0
CA002067341A 1990-08-08 1991-08-08 Methode de synthese des derives de la prostaglandine Expired - Fee Related CA2067341C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9002596-6 1990-08-08
SE9002596A SE9002596D0 (sv) 1990-08-08 1990-08-08 A method for synthesis of prostaglandin derivatives

Publications (2)

Publication Number Publication Date
CA2067341A1 true CA2067341A1 (fr) 1992-02-09
CA2067341C CA2067341C (fr) 1997-09-30

Family

ID=20380110

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002067341A Expired - Fee Related CA2067341C (fr) 1990-08-08 1991-08-08 Methode de synthese des derives de la prostaglandine

Country Status (11)

Country Link
EP (1) EP0495069B1 (fr)
JP (1) JP2670521B2 (fr)
AT (1) ATE133162T1 (fr)
BG (1) BG61143B1 (fr)
CA (1) CA2067341C (fr)
DE (1) DE69116541T2 (fr)
HU (1) HUT62874A (fr)
RO (1) RO109332B1 (fr)
RU (1) RU2073668C1 (fr)
SE (1) SE9002596D0 (fr)
WO (1) WO1992002496A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223537A (en) * 1991-07-23 1993-06-29 Kabi Pharmacia Ab Method and composition for treatment of gastric and duodenal disorders
US5516796A (en) * 1994-03-24 1996-05-14 Kabi Pharmacia Ab Thioprostaglandins and -prostaglandin-like compounds and therapeutic uses thereof
WO1998021180A1 (fr) * 1995-06-07 1998-05-22 Alcon Laboratories, Inc. Prostaglandines aryle ou heteroaryle a conformation rigide utilisees dans le traitement des glaucomes
GB0112699D0 (en) 2001-05-24 2001-07-18 Resolution Chemicals Ltd Process for the preparation of prostglandins and analogues thereof
GB0126076D0 (en) * 2001-10-31 2001-12-19 Cascade Biochem Ltd Improvements relating to prostaglandins and their analogues
JP2008037782A (ja) * 2006-08-04 2008-02-21 Daiichi Fine Chemical Co Ltd プロスタグランジン誘導体の製造方法
US7642370B2 (en) 2006-08-07 2010-01-05 Daiichi Fine Chemical Co., Ltd. Method for preparing prostaglandin derivative
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
CA2777290C (fr) 2009-10-16 2016-06-28 Cayman Chemical Company, Incorporated Procede de preparation de prostaglandines de la serie f
PL2723714T3 (pl) * 2011-06-02 2018-02-28 CHINOIN Zrt. Nowe sposoby otrzymywania amidów prostaglandyn

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES416865A1 (es) * 1972-07-13 1976-03-01 Pfizer Procedimiento para preparar w-pentanorprostaglandinas sus- tituidas en la posicion 15.
US3962312A (en) * 1972-09-21 1976-06-08 Ono Pharmaceutical Company 9,11,15-Trihydroxy prost-5-enoic acid analogues

Also Published As

Publication number Publication date
RU2073668C1 (ru) 1997-02-20
WO1992002496A1 (fr) 1992-02-20
BG61143B1 (bg) 1996-12-31
HUT62874A (en) 1993-06-28
JPH05502043A (ja) 1993-04-15
CA2067341C (fr) 1997-09-30
RO109332B1 (ro) 1995-01-30
SE9002596D0 (sv) 1990-08-08
AU645129B2 (en) 1994-01-06
JP2670521B2 (ja) 1997-10-29
DE69116541D1 (en) 1996-02-29
EP0495069A1 (fr) 1992-07-22
ATE133162T1 (de) 1996-02-15
AU8391591A (en) 1992-03-02
EP0495069B1 (fr) 1996-01-17
DE69116541T2 (de) 1996-09-19
BG96194A (bg) 1993-12-24

Similar Documents

Publication Publication Date Title
DK0594291T3 (da) Fremgangsmåder til fremstilling af 13-etherderivater af milbemyciner og mellemprodukter dertil
DE68906552D1 (de) Camptothecin-derivate und verfahren zu ihrer herstellung.
MY104626A (en) A 1-phenylimidazole derivative and its production and use.
AU648319B2 (en) Process for the stereoselective preparation of phenylisoserin derivatives
CA2067341A1 (fr) Methode de synthese des derives de la prostaglandine
HUT49986A (en) Composition comprising alpha, omega-aminoalcohol derivative as active ingredient, for expelling insects and mites and process for producing new alpha, omega-aminoalcohol derivatives
CA2027351A1 (fr) Emulsion lipidique renfermant un analogue de prostaglandine
EP0472733A4 (en) Phenanthrene derivative
SE8305918L (sv) Mellanprodukter for framstellning av bensimidazolderivat
CA2191874A1 (fr) Procedes et intermediaires nouveaux destines a la preparation de derives de piperazine
HK117993A (en) Glycerol derivatives
CA2021733A1 (fr) Derive cycloalcanol substitue par un groupe azole, procede pour sa production et son utilisation comme fongicide agricole et horticole
RU94033098A (ru) Способ производных 1-замещенного-5/4h/-тетразолинона
PL324274A1 (en) Method of obtaining derivatives of cholecalciferol and novel intermediate compounds
EP0926147A4 (fr) Procede pour preparer des composes de 1,3-dioxolane-4-methanol
AU600054B2 (en) 2,5,6,7-tetranor-18,18,19,19-tetradehydro-4,8-inter-m- phenylene pgi2 derivatives
UA43338C2 (uk) Похідні бензолу
ES2118993T3 (es) Procedimiento para la preparacion de derivados de sulfonilurea.
GEP20022679B (en) Process For The Synthesis Of Chloropurine Intermediates
IE893258L (en) New 2-carbonyl substituted n,n'-di-(trimethoxybenzoyl)¹piperazines, process for preparing the same and¹therapeutical compounds containing them
EP0621268A4 (fr) Nouveau derive d'azole, sa production et composition pharmaceutique.
EP0250755A3 (en) Fluorine derivatives of vitamin d3 and process for producing the same
MY105057A (en) A process for preparing naphthalene derivatives
EP0328669A4 (fr) Composes derives du chalcone.
WO1992010193A3 (fr) Derives d'homo-prostaglandines utilises comme hypotenseurs oculaires

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed